Thus, our results indicate that EML4-ALK-mediated stem-like phenotypes are dependent on the ALK activity and anti-tumor effects caused by crizotinib treatment at least partially are related with loss of stem-like potentials in EML4-ALK+ NSCLC cells. The gene discussed is ALK; the disease is neoplasm.